Sfoglia per Autore
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study).
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP
High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study
2004-01-01 BARBERO P; VERDUN E; BERGUI M; PIPIERI A; CLERICO M; CUCCI A; RICCI A; BERGAMASCO B; DURELLI L
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial
2004-01-01 P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP
Looking for treatment response indicator. real- time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors in Multiple Sclerosis patients treated with ifn beta 1b: correlation with mri response
2005-01-01 A. CUCCI; A. RICCI; M. CLERICO; E. VERDUN; L. GIORDANO; P. BARBERO; A. PIPIERI; B. FERRERO; E. FESTA; L. DURELLI
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a
2005-01-01 E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation
2005-01-01 A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP
To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved.
2005-01-01 A. RICCI; P. BARBERO; A PIPIERI; B. FERRERO; M. CUCCI; M. CLERICO; G. CONTESSA; L. GIORDANO; L. DURELLI; AND THE OPTIMS STUDY GROUP
Mxa protein: correlation with magnetic resonance imaging response in relapsing-remitting multiple sclerosis patients treated with two different ifn beta doses
2005-01-01 A. RICCI; P. BARBERO; A. PIPIERI; E. VERDUN; M. CLERICO; A. CUCCI; L. GIORDANO; B. FERRERO; E. FESTA; L. DURELLI; THE OPTIMS STUDY GROUP
Interferon beta-1b 500 mcg every-other-day in ms patients. Clinical and mri results
2005-01-01 P. BARBERO; A. PIPIERI; M. BERGUI; E. VERSINO; L. GIORDANO; M. CLERICO; A. RICCI; A. CUCCI; G. CONTESSA; M.L. GENESIA; E. PUCCI; E. CARTECHINI; L. MANNESCHI; I. PESCI; G; GIULIANI; E. MONTANARI; L. DURELLI
Real-time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors, in patients treated with ifn beta 1b: correlation with mri response and evaluation of a prognostic marker in ms.
2005-01-01 A. CUCCI; A. RICCI; M. CLERICO; P. BARBERO; A. PIPIERI; B. FERRERO; E. FESTA; G.CONTESSA; L. GIORDANO; A. ROVERA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP
IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment
2005-01-01 M. Clerico; A. Pipaeri; P. Barbero; M. Bergui; F. Bruno; E. Verdun; L. Giordano; A. Ricci; E. Pucci; G. Giuliani; E. Cartechini; L. Manneschi; E. Montanari; E. Versino; A. Cucci; L. Durelli
Interferon beta-1b 500 mcg every-other-day, subcutaneously in ms patients. Tolerability, clinical and mri results after one year of treatment
2005-01-01 M. CLERICO; A. PIPIERI; P. BARBERO; M. BERGUI; B. FERRERO; E. VERDUN; L. GIORDANO; A. RICCI; E. PUCCI; G. GIULIANI; E. CARTECHINI; L. MANNESCHI; E. MONTANARI; E. VERSINO; A. CUCCI; L. DURELLI
Mxa protein in ms patients treated with different doses of ifn beta-1b (the optims study): correlation with treatment response, ifn beta dose, and neutralizing antibodies (nab)occurrence
2005-01-01 A. RICCI; L. GIORDANO; A. CUCCI; M. CLERICO; E. VERDUN; P. BARBERO; A. PIPIERI; B. FERRERO; E. FESTA; E. VERSINO; L. DURELLI; AND THE OPTIMS STUDY GROUP
MRNA levels of cytokines, chemokines and chemokine receptors as indicator of treatment response in Multiple Sclerosis patients treated with interferon-beta 1b
2006-01-01 A. CUCCI; G. CONTESSA; M. CLERICO; P. BARBERO; A. PIPIERI; B. FERRERO; M. L. GENESIA; E. FESTA; A. ROVERA; A. TAVELLA; L. DURELLI; FOR THE OPTIMS STUDY GROUP
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
2006-01-01 A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
Indicators of treatment response to interferon beta in ms. mxa protein, il-10 mrna or mri?
2006-01-01 G. CONTESSA; M. CLERICO; P. BARBERO; B. FERRERO; A. CUCCI; E. VERSINO; G. GIULIANI; E. MONTANARI; L. DURELLI; THE OPTIMS STUDY GROUP
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
2006-01-01 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
High-dose (375 mcg) interferon beta-1b treatment of multiple sclerosis and neutralising antibodies. Long-term follow-up
2006-01-01 L. Durelli; A. Ricci; P. Bergui; A. Pipieri; A. Cucci; B. Festa; A. Rovera; G. Contessa; M. Bergui; E. Versino; M. Clerico
Using biological (mxa protein or il-10 mrna level) or mri indicators for assessing treatment response to interferon-beta
2006-01-01 G. CONTESSA; M. CLERICO; P. BARBERO; B. FERRERO; M.A. CUCCI; L. DELFICO; E. VERSINO; G. GIULIANI; E. MONTANARI; L. DURELLI; FOR THE OPTIMS STUDY GROUP
Is the combination of different treatment responseindicators useful to identify patients with a sub-optimal response to interferon beta?
2007-01-01 C. Rivoiro; R. Barbero; A. Cucci; G. Contessa; C. Ferrero; M. Bergui; E. Versino; B. Ferrero; G. Giuliani; E. Montanari; M. Clerico
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study). | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP | |
| High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study | 2004 | BARBERO P; VERDUN E; BERGUI M; PIPIERI A; CLERICO M; CUCCI A; RICCI A; BERGAMASCO B; DURELLI L | |
| Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial | 2004 | P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP | |
| Looking for treatment response indicator. real- time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors in Multiple Sclerosis patients treated with ifn beta 1b: correlation with mri response | 2005 | A. CUCCI; A. RICCI; M. CLERICO; E. VERDUN; L. GIORDANO; P. BARBERO; A. PIPIERI; B. FERRERO; E. FESTA; L. DURELLI | |
| Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a | 2005 | E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP | |
| Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation | 2005 | A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP | |
| To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved. | 2005 | A. RICCI; P. BARBERO; A PIPIERI; B. FERRERO; M. CUCCI; M. CLERICO; G. CONTESSA; L. GIORDANO; L. DURELLI; AND THE OPTIMS STUDY GROUP | |
| Mxa protein: correlation with magnetic resonance imaging response in relapsing-remitting multiple sclerosis patients treated with two different ifn beta doses | 2005 | A. RICCI; P. BARBERO; A. PIPIERI; E. VERDUN; M. CLERICO; A. CUCCI; L. GIORDANO; B. FERRERO; E. FESTA; L. DURELLI; THE OPTIMS STUDY GROUP | |
| Interferon beta-1b 500 mcg every-other-day in ms patients. Clinical and mri results | 2005 | P. BARBERO; A. PIPIERI; M. BERGUI; E. VERSINO; L. GIORDANO; M. CLERICO; A. RICCI; A. CUCCI; G. CONTESSA; M.L. GENESIA; E. PUCCI; E. CARTECHINI; L. MANNESCHI; I. PESCI; G; GIULIANI; E. MONTANARI; L. DURELLI | |
| Real-time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors, in patients treated with ifn beta 1b: correlation with mri response and evaluation of a prognostic marker in ms. | 2005 | A. CUCCI; A. RICCI; M. CLERICO; P. BARBERO; A. PIPIERI; B. FERRERO; E. FESTA; G.CONTESSA; L. GIORDANO; A. ROVERA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP | |
| IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment | 2005 | M. Clerico; A. Pipaeri; P. Barbero; M. Bergui; F. Bruno; E. Verdun; L. Giordano; A. Ricci; E. Pucci; G. Giuliani; E. Cartechini; L. Manneschi; E. Montanari; E. Versino; A. Cucci; L. Durelli | |
| Interferon beta-1b 500 mcg every-other-day, subcutaneously in ms patients. Tolerability, clinical and mri results after one year of treatment | 2005 | M. CLERICO; A. PIPIERI; P. BARBERO; M. BERGUI; B. FERRERO; E. VERDUN; L. GIORDANO; A. RICCI; E. PUCCI; G. GIULIANI; E. CARTECHINI; L. MANNESCHI; E. MONTANARI; E. VERSINO; A. CUCCI; L. DURELLI | |
| Mxa protein in ms patients treated with different doses of ifn beta-1b (the optims study): correlation with treatment response, ifn beta dose, and neutralizing antibodies (nab)occurrence | 2005 | A. RICCI; L. GIORDANO; A. CUCCI; M. CLERICO; E. VERDUN; P. BARBERO; A. PIPIERI; B. FERRERO; E. FESTA; E. VERSINO; L. DURELLI; AND THE OPTIMS STUDY GROUP | |
| MRNA levels of cytokines, chemokines and chemokine receptors as indicator of treatment response in Multiple Sclerosis patients treated with interferon-beta 1b | 2006 | A. CUCCI; G. CONTESSA; M. CLERICO; P. BARBERO; A. PIPIERI; B. FERRERO; M. L. GENESIA; E. FESTA; A. ROVERA; A. TAVELLA; L. DURELLI; FOR THE OPTIMS STUDY GROUP | |
| A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b | 2006 | A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| Indicators of treatment response to interferon beta in ms. mxa protein, il-10 mrna or mri? | 2006 | G. CONTESSA; M. CLERICO; P. BARBERO; B. FERRERO; A. CUCCI; E. VERSINO; G. GIULIANI; E. MONTANARI; L. DURELLI; THE OPTIMS STUDY GROUP | |
| A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b | 2006 | A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| High-dose (375 mcg) interferon beta-1b treatment of multiple sclerosis and neutralising antibodies. Long-term follow-up | 2006 | L. Durelli; A. Ricci; P. Bergui; A. Pipieri; A. Cucci; B. Festa; A. Rovera; G. Contessa; M. Bergui; E. Versino; M. Clerico | |
| Using biological (mxa protein or il-10 mrna level) or mri indicators for assessing treatment response to interferon-beta | 2006 | G. CONTESSA; M. CLERICO; P. BARBERO; B. FERRERO; M.A. CUCCI; L. DELFICO; E. VERSINO; G. GIULIANI; E. MONTANARI; L. DURELLI; FOR THE OPTIMS STUDY GROUP | |
| Is the combination of different treatment responseindicators useful to identify patients with a sub-optimal response to interferon beta? | 2007 | C. Rivoiro; R. Barbero; A. Cucci; G. Contessa; C. Ferrero; M. Bergui; E. Versino; B. Ferrero; G. Giuliani; E. Montanari; M. Clerico |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile